CSIMarket
 
Marizyme Inc   (MARZ)
Other Ticker:  
 
 
Price: $29.5436 $0.12 0.407%
Day's High: $29.5436 Week Perf: 0.97 %
Day's Low: $ 29.41 30 Day Perf: 4.59 %
Volume (M): 1 52 Wk High: $ 29.85
Volume (M$): $ 21 52 Wk Avg: $27.75
Open: $29.41 52 Wk Low: $25.25



 Market Capitalization (Millions $) 1,353
 Shares Outstanding (Millions) 46
 Employees -
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -79
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Marizyme Inc
Marizyme is a life sciences company that specializes in developing and commercializing innovative therapies and products that utilize enzymes. The company is dedicated to improving human and animal health by harnessing the power of enzymes to create safe, effective, and affordable therapies.

The company was founded in 2017 by biological engineers with deep experience in the development of cutting-edge enzyme technologies. Marizyme's team has a strong background in the discovery, optimization, and commercialization of enzymes, as well as in the development of novel applications for enzymes in healthcare, agriculture, and beyond.

Marizyme's lead product candidate is DuraGraft, a proprietary solution that improves the outcomes of vascular surgeries. DuraGraft is an enzymatic solution that is designed to improve the functionality and quality of vascular grafts used in bypass surgeries. The company has completed clinical trials of DuraGraft, which demonstrated statistically significant improvements in graft outcomes.

In addition to DuraGraft, Marizyme has a pipeline of other product candidates in development, including enzyme therapies for conditions such as cystic fibrosis, cancer, and spinal cord injury. The company is also exploring potential applications of enzymes in areas such as food and agriculture.

To support its research and development efforts, Marizyme has established partnerships with leading academic institutions and research organizations. The company has also secured funding from a variety of sources, including private investors, government grants, and strategic partnerships.

Overall, Marizyme is a pioneering life sciences company that is working to bring the power of enzymes to the forefront of modern medicine. The company's innovative approach has the potential to transform the treatment of a wide range of conditions and improve the lives of millions of people around the world.


   Company Address: 555 Heritage Drive Jupiter 33458 FL
   Company Phone Number: 400-3123   Stock Exchange / Ticker: MARZ
   MARZ is expected to report next financial results on March 23, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Ufp Technologies Inc

Strong Earnings Per Share (EPS) Highlight UFP Technologies Inc's Impressive Double-Digit Revenue Growth in Latest Fiscal Report2.

UFP Technologies Inc, a designer and custom manufacturer of engineered solutions primarily for the medical market, recently released its financial results for the period of October to December 31, 2023. The company reported a significant increase in profit per share, which rose by 37.57% to $1.49 per share compared to the prior year period. Additionally, their revenue increased by 10.785% to $101.08 million.
Compared to the preceding financial reporting period, UFP Technologies Inc experienced a slight decrease in net profit per share by -2.03%, from $1.52 per share. However, their revenue advanced by 0.325% from $100.75 million. Despite the minor dip in net profit, the company's net income for the fiscal time-frame ending December 31, 2023, increased by 37.18% to $11.608 million compared to the previous year period, where net earnings were $8.462 million.

Lemaitre Vascular Inc

Lemaitre Vascular Inc's Meteoric Rise: Profits and Revenue Soar in Fiscal Quarter

LMAT had a remarkable fiscal period, with notable growth in both profit per share and revenue. Profit per share increased by 48.89% to $0.37 per share, while revenue rose by 19.825% to $49.07 million compared to the prior year period. This shows that Lemaitre Vascular Inc has outpaced its sector contemporaries in the Medical Equipment and Supplies sector, where the rest of the sector reported a revenue growth of only 7.86% during the same period.
The company's income per share also saw a positive growth of 12.75% from the preceding reporting period, from $0.33 to $0.37 per share. Revenue also grew by 4.823% from $46.82 million to $49.07 million. This indicates that the company's financial performance is strong and heading in the right direction.

Livanova Plc

Livanova Plc Surges Ahead with $110.65 Million Tax Refund Boost

Livanova Plc, a leading company in the Medical Equipment and Supplies sector, has reported impressive financial results for the period closing on December 31, 2023. The company witnessed a significant increase in its income per share, which soared by an impressive 859.07% to $0.29 per share. Furthermore, its revenue experienced a boost of 12.832% to reach $310.15 million, compared to the previous year.
Compared to its competitors in the Medical Equipment and Supplies sector, Livanova Plc's revenue growth was even more remarkable. In the fourth quarter of 2023, most corporations in the sector experienced a 7.86% increase in revenue relative to the same period a year ago. However, Livanova Plc outperformed its contemporaries by achieving a higher revenue growth rate.

Merit Medical Systems Inc

Despite Strong Revenue Growth, Merit Medical Systems Inc. Sees Decline in Earnings for Q4 2023

As a financial analyst covering Merit Medical Systems Inc, I have dug deep into the recent financial results released by the company for the fourth quarter of 2023. Despite a substantial increase in revenue of 10.442% to $324.05 million, the company saw a decline in earnings per share (EPS) of -18.93% to $0.47 per share. This decline in EPS may be concerning to investors, especially considering the 6.1% improvement in income from the previous reporting period.
One factor that may have contributed to the decline in EPS is the company's shift in focus towards boosting sales, as indicated by the 10.5% increase in operating earnings to $33.612 million. While this may have impacted the bottom line in the short term, it shows a strategic decision to invest in growth opportunities. Additionally, the increase in accounts receivable and the rise in operating earnings point to rising demand and a positive outlook for future revenue growth.

Patterson Companies Inc

Decline in Earnings Despite Revenue Increase at Patterson Companies Inc over November to January 27, 2024

Patterson Companies Inc Facing Challenges but Remains Optimistic for Future Growth
Patterson Companies Inc, a leading provider of medical equipment and supplies, experienced a slight revenue improvement of 0.947% in the November to January 27, 2024 interval. However, this was not enough to prevent a decline in income by -5.45% compared to the corresponding reporting period the previous year. Despite these challenges, Patterson Companies Inc remains optimistic about its future growth prospects.
In the third quarter of 2024, Patterson Companies Inc's revenue stood at $1.62 billion, with earnings per share at $0.52. To truly understand the company's performance during this period, it is essential to compare it with the on average Medical Equipment and Supplies industry. When doing so, it becomes clear that Patterson Companies Inc has underachieved, as its contemporaries reported a top-line improvement of 7.86% relative to the third quarter of 2023.






 

Marizyme Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com